ALLOX is a spin-off of the Centre for Genomic Regulation (CRG) in Barcelona, founded by researchers Ben Lehner, Júlia Domingo, Pablo Baeza, and André Faure. It is a techbio company building the next generation of tools to predict and design new drugs based on allosteric regulation.

"Our technology enables us to gather data on the biophysical consequences of mutations at an unprecedented speed. In just 3 or 4 months, we can generate an amount of data comparable to all previously published data combined. This provides us with a unique opportunity to learn from high-quality data. Our ultimate goal is to build computational model that allows us to predict allosteric sites entirely in silico, without the need for experiments."

"It is evident that women are much less represented in executive positions, not only in the biotech sector. The situation is improving, but we still have a long way to go."

Read the full interview in El·lipse

Júlia Domingo is the CEO of the latest spin-off from the Centre for Genomic Regulation, ALLOX, which has been operational for about six months.